Epstein-Barr virus nuclear antigen 1 peptide–Major Histocompatibility Complex class I complex (EBV EBNA1–MHC I complex)

The Epstein-Barr virus nuclear antigen 1 (EBNA1) peptide–Major Histocompatibility Complex (MHC) class I complex is a pivotal immunological target for the treatment of EBV-associated malignancies and certain autoimmune conditions. EBNA1 is a viral protein required for the maintenance, replication, and segregation of the EBV genome, and it is uniquely expressed in all EBV-infected cells, including those in Nasopharyngeal Carcinoma, Burkitt Lymphoma, and Post-Transplant Lymphoproliferative Disorder (PTLD) (PMID: 25607443, 31434705). Because EBNA1 is an intracellular protein, it is traditionally difficult to target with conventional antibodies; however, its processed peptides (such as the HLA-A*02:01-restricted VLKDAIKDL epitope) are presented on the cell surface by MHC class I molecules (PMID: 15155838). This presentation allows the immune system, or engineered therapies like TCR-T cells and TCR-like antibodies, to identify and eliminate infected cells (PMID: 29109440). Current therapeutic development focuses on leveraging this complex to provide highly specific immunotherapy, though challenges include tumor-mediated HLA downregulation and the risk of cross-reactivity with similar human self-peptides (PMID: 36513115).

Other names

EBNA1-HLA complexEBNA1 pMHCEBNA1 peptide-HLA-A*02:01 complexEBV EBNA1-MHC class IEBNA1-MHC I

Therapeutic agents target the EBNA1 peptide–MHC I complex to trigger directed cytotoxic immune responses. TCR-engineered T cells recognize the complex via synthetic T-cell receptors, leading to granzyme/perforin-mediated apoptosis of the target cell. TCR-like antibodies or bispecific T-cell engagers (BiTEs) bind the complex to recruit and activate endogenous T cells or mediate antibody-dependent cellular cytotoxicity (ADCC).